Silo Pharma Amends S-1 Registration Statement

TL;DR

Silo Pharma (SILO) filed an S-1/A amendment, looks like they're still prepping for a stock event.

AI Summary

Silo Pharma, Inc. filed an S-1/A amendment on July 25, 2024, for its registration statement. The company, formerly known as Uppercut Brands, Inc., Point Capital, Inc., and Gold Swap Inc., is incorporated in Nevada and has its principal executive offices in Sarasota, Florida. This filing is an amendment to a previous S-1 registration statement.

Why It Matters

This amendment to Silo Pharma's S-1 filing indicates ongoing efforts to register securities, which could lead to future public offerings or stock issuances.

Risk Assessment

Risk Level: medium — S-1/A filings are typically associated with upcoming stock offerings or significant corporate actions, which inherently carry market and execution risks.

Key Numbers

• 333-280855 — SEC File Number (Identifies the specific registration filing with the SEC.)
• 20240725 — Filing Date (The date this amendment to the S-1 was filed.)

Key Players & Entities

• Silo Pharma, Inc. (company) — Registrant
• July 25, 2024 (date) — Filing date of S-1/A
• 333-280855 (registration_number) — SEC registration number
• Eric Weisblum (person) — Chief Executive Officer
• Uppercut Brands, Inc. (company) — Former company name
• Point Capital, Inc. (company) — Former company name
• Gold Swap Inc (company) — Former company name
• Nevada (jurisdiction) — State of incorporation
• Sarasota, Florida (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.0001 — ares”) of common stock, par value $0.0001 per share (“Common Stock”),
• $2.06 — Shares”), at an exercise price of $2.06 per share; issued by us to certain accr
• $2.725 — Agent”), at an exercise price of $2.725 per share and (iii) certain common stoc
• $6.25 — Shares”), at an exercise price of $6.25 per share, issued by us to Laidlaw & Co
• $2.44 million — gregate gross proceeds of approximately $2.44 million. However, we cannot predict when and in
• $2.18 — rted sale price of our Common Stock was $2.18. This offering will terminate on the

Filing Documents

• ea0209935-s1a1_silopharma.htm (S-1/A) — 318KB
• ea020993501ex23-1_silophar.htm (EX-23.1) — 3KB
• image_001.jpg (GRAPHIC) — 15KB
• image_002.jpg (GRAPHIC) — 40KB
• image_003.jpg (GRAPHIC) — 14KB
• 0001013762-24-001151.txt ( ) — 418KB

RISK FACTORS

RISK FACTORS 9 JUNE 2024 REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT 10 SEPTEMBER 2022 PUBLIC OFFERING 10 SELLING SHAREHOLDERS 11

USE OF PROCEEDS

USE OF PROCEEDS 14 DIVIDEND POLICY 14

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 15

DESCRIPTION OF SECURITIES THAT THE SELLING SHAREHOLDERS ARE OFFERING

DESCRIPTION OF SECURITIES THAT THE SELLING SHAREHOLDERS ARE OFFERING 16 PLAN OF DISTRIBUTION 16 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITY 18 LEGAL MATTERS 18 EXPERTS 18 WHERE YOU CAN FIND MORE INFORMATION 18 INCORPORATION OF DOCUMENTS BY REFERENCE 19 i ABOUT THIS PROSPECTUS This prospectus relates to the offer and resale of up to an aggregate of 1,043,739 shares (the “Shares”) of common stock, par value $0.0001 per share (“Common Stock”), of Silo Pharma, Inc. (the “Company”, “we”, “us” or “our”), consisting of shares of Common Stock issuable upon exercise of: (i) common stock purchase warrants (the “June 2024 Investor Warrants”), to purchase up to 917,432 shares of Common Stock (the “June 2024 Investor Warrant Shares”), at an exercise price of $2.06 per share; issued by us to certain accredited investors on June 6, 2024 in a concurrent private placement and registered direct transaction pursuant to a securities purchase agreement, dated as of June 4, 2024 (the “June 2024 Purchase Agreement”); (ii) common stock purchase warrants (the “June 2024 Placement Agent Warrants”) to purchase 68,807 shares of Common Stock (the “June 2024 Placement Agent Warrant Shares”) issued to H.C. Wainwright & Co., LLC, as exclusive placement agent (the “Placement Agent”), at an exercise price of $2.725 per share and (iii) certain common stock purchase warrants (the “September 2022 Underwriter Warrants,” together with the June 2024 Investor Warrants and the June 2024 Placement Agent Warrants, the “Warrants”), to purchase up to 57,500 shares of Common Stock (the “September 2022 Underwriter Warrant Shares,” together with the June 2024 Investor Warrant Shares and the June 2024 Placement Agent Warrant Shares, the “Warrant Shares”)), at an exe

View Full Filing

View this S-1/A filing on SEC EDGAR